Aridis Pharmaceuticals (NASDAQ:ARDS) posted its quarterly earnings results on Monday. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.19), Bloomberg Earnings reports. Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%.
ARDS opened at $8.15 on Wednesday. The stock’s 50 day moving average is $9.64. Aridis Pharmaceuticals has a 1 year low of $6.91 and a 1 year high of $13.85. The company has a market cap of $66.08 million and a price-to-earnings ratio of -1.16.
ARDS has been the topic of several recent research reports. ValuEngine upgraded Aridis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Maxim Group restated a “buy” rating on shares of Aridis Pharmaceuticals in a research report on Wednesday, July 31st. Zacks Investment Research upgraded Aridis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Finally, Northland Securities restated a “buy” rating and set a $40.00 price target on shares of Aridis Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $27.50.
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Recommended Story: Diversification Important in Investing
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.